Danny Rischin

Patient-report symptom severity, health-related quality of life and emotional distress trajectories during and after radiotherapy for HPV-associated oropharyngeal cancer: a XXXX.XXXX secondary analysis.

Lachlan McDowell, Mathias Bressel, Madeleine T King, June Corry, Lizbeth Kenny, Sandro Porceddu, Christopher Wratten, Andrew Macann, James E Jackson, Danny Rischin

Journal article  |  2023  |  Int J Radiat Oncol Biol Phys

PURPOSE/OBJECTIVES: This secondary analysis of clinical trial XXXX.XXXX, involving patients with human papillomavirus-associated o..

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.

Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Tomohide Tamura, Kazuhiko Nakagawa, Jean-Yves Douillard, Yutaka Nishiwaki, Johan Vansteenkiste, Shinzoh Kudoh, Danny Rischin, Richard Eek, Takeshi Horai, Kazumasa Noda, Ichiro Takata, Egbert Smit, Steven Averbuch, Angela Macleod, Andrea Feyereislova, Rui-Ping Dong, José Baselga

Journal article  |  2023  |  J Clin Oncol

PURPOSE: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a nov..

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.

Kevin J Harrington, Barbara Burtness, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Irene Brana, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett GM Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Jianxin Lin, Burak Gumuscu, Ramona F Swaby, et al.

Journal article  |  2023  |  J Clin Oncol

PURPOSE: Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in recurrent/metastatic head and neck squamous cell ca..

Patient- and Clinician-Reported Outcomes in Human Papillomavirus-Associated Tonsillar Carcinoma Treated With Unilateral and Bilateral Intensity Modulated Radiation Therapy-A Substudy From TROG 12.01.

Lachlan McDowell, Danny Rischin, Madeleine King, Lizbeth Kenny, Sandro Porceddu, Christopher Wratten, Andrew Macann, James E Jackson, Mathias Bressel, Tsien Fua, Charles Lin, Chen Liu, June Corry

Journal article  |  2023  |  Int J Radiat Oncol Biol Phys

PURPOSE: The aim of this TROG 12.01 substudy was to report longitudinal variations in patient- (PRO) and clinician-reported outcom..

The Current Treatment Landscape of Cutaneous Squamous Cell Carcinoma.

Chia Yuen Chong, Michelle S Goh, Sandro V Porceddu, Danny Rischin, Annette M Lim

Journal article  |  2023  |  Am J Clin Dermatol

Non-melanoma skin cancers (NMSCs) are the most common form of skin cancer worldwide. The global incidence of cutaneous squamous ce..

The negative predictive value of FDG PET/CT staging in early oropharyngeal squamous cell carcinoma and implications to transoral robotic surgery patient selection.

Mario Tapia, Jamil Manji, Kaman Dhillon, Stephen Kleid, Samuel Flatman, Jessica Prasad, Anthony Cardin, Tsien Fua, Danny Rischin, Benjamin Dixon, Matthew J R Magarey

Journal article  |  2022  |  Oral Oncol

OBJECTIVES: Our objective was to determine the negative predictive value (NPV) of preoperative FDG PET/CTfor detecting locoregiona..

C-POST Protocol Update: A Phase 3, Randomized, Double-Blind Study of Adjuvant Cemiplimab vs. Placebo Post Surgery and Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma

D Rischin, D Brungs, F Day, H Christie, VA Patel, G Adams, JE Jackson, MDLV Schurmann, D Kirtbaya, TM Shin, CD Hart, E Stankevich, S Li, I Lowy, H Han, MG Fury, S Porceddu

Journal article  |  2022  |  International Journal of Radiation Oncology*Biology*Physics

Head and Neck Symptom Severity (HNSS) and Health-Related Quality of Life (HRQL) Trajectories during and after Chemoradiotherapy (CRT) for HPV-Associated Oropharyngeal Cancer (HPVOPC): A TROG 12.01 Secondary Analysis

LJ McDowell, M Bressel, MT King, J Corry, L Kenny, S Porceddu, C Wratten, AMJ Macann, JE Jackson, D Rischin

Journal article  |  2022  |  International Journal of Radiation Oncology*Biology*Physics

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma

ND Gross, DM Miller, N Khushalani, V Divi, ES Ruiz, F Meier, YB Su, PL Swiecicki, J Atlas, JL Geiger, A Hauschild, JH Choe, BGM Hughes, D Schadendorf, VA Patel, J Homsi, JM Taube, AM Lim, R Ferrarotto, HL Kaufman, et al.

Journal article  |  2022  |  NEW ENGLAND JOURNAL OF MEDICINE

BACKGROUND: In a pilot study involving patients with cutaneous squamous-cell carcinoma, a high percentage of patients had a pathol..

814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3

MR Migden, C Schmults, N Khushanlani, A Guminski, AL Chang, K Lewis, G Ansstas, SE Bowyer, BGM Hughes, D Schadendorf, B Modi, L Dunn, L Flatz, A Hauschild, S-Y Yoo, J Booth, F Seebach, I Lowy, MG Fury, D Rischin

Journal article  |  2022  |  Annals of Oncology